July 19 /PRNewswire/ -- AxCell Biosciences Corporation, a wholly owned
subsidiary of Cytogen Corporation today announced that it was invited to
present at "Investing in & Commercializing New Technologies for Proteomics" on September 22, 2000
in San Francisco. The conference, which features over 30 speakers, including Wall Street analysts and
bankers, venture capitalists, and representatives from academia, pharmaceutical firms and emerging
proteomics companies, is sponsored by Global Business Research Ltd.
"Now that the human genome has been sequenced, we are beginning to undertake the real challenge:
understanding how aberrations in protein interactions within cells cause disease and how specific
intervention in these pathways can treat disease," said John D. Rodwell, Ph.D., AxCell's acting
President and Chief Technical Officer. "In addition to using our high- throughput methods to chart
signaling pathways rapidly and identify potential drug targets, we believe that researchers will be able
to use our protein arrays to test whether lead compounds cross-react with similar protein targets. Such
cross-protein interactions represent the unwanted side-effects which often limit lead compound
development. Overall, we believe that our customers will have a unique advantage: the combination of
pathway mapping and target identification, coupled with efficient lead optimization."
snip<>
Jim |
